The Hydropothecary (HEXO) has notable insider net $ selling

The Hydropothecary (T:HEXO)

Edward Chaplin, a Senior Officer, disposed 30,000 Common Shares on a direct ownership basis at prices ranging from $4.500 and $4.520 through the public market on August 15th, 2018. This represents a $135,265 divestment of the company's shares and an account share holdings change of -47.6%.

Sebastien G. St-Louis, a Senior Officer, disposed 429,168 Common Shares on a direct ownership basis at prices ranging from $4.130 and $4.310 through the public market between August 13th, 2018 and August 14th, 2018. The insider also acquired 412,500 Common Shares on a direct ownership basis at prices ranging from $0.160 and $0.750 through an exercise of options on August 13th, 2018. The insider also acquired 16,668 Common Shares on a direct ownership basis at a price of $0.830 through an exercise of warrants on August 13th, 2018. This represents a $1,612,041 net divestment of the company's shares and an account share holdings change of 0%.

Hydropothecary Corp, formerly BFK Capital Corp, is a Canada-based company, which is an authorized licensed producer and distributor of medical marijuana under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company provides naturally and rigorously tested medical marijuana, grown without the use of synthetic pesticides in greenhouses. In addition to medical marijuana production and sales, the Company explores research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the Company is investigating the development and patenting of novel technologies related to medical marijuana, as well as the import and export of medical marijuana.